AEON Biopharma
AEON
24 hedge funds and large institutions have $8.73M invested in AEON Biopharma in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.35% → 0.33% (-0.02%)
8% less funds holding
Funds holding: 26 → 24 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
92% less capital invested
Capital invested by funds: $103M → $8.73M (-$94.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
+$298K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$160K |
| 3 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$150K |
| 4 |
BlackRock
New York
|
+$55.8K |
| 5 |
KL
KIM LLC
Wichita,
Kansas
|
+$51.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$522K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$248K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$194K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$167K |
| 5 |
JP Morgan Chase
New York
|
-$94.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Shaolin Capital Management
Miami,
Florida
| – | -$248K | -297 | Closed |
|
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$167K | -200 | Closed |
|
28
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$10 | -13 | Closed |
|
|
CFM
29
Catalyst Funds Management
Sydney NSW,
Australia
| – | -$3.31K | -4 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | -$1.61K | -2 | Closed |
|
AEON Hedge Fund Activity: Q2 2024 in Review
24 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2024, worth a combined $8.73M — down 92% from $103M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of AEON and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $298K. The largest seller was Goldman Sachs, cutting an estimated $522K.
- 24 institutional investors held AEON Biopharma (AEON) as of Q2 2024, down from 26 in Q1 2024.
- Funds reported $8.73M of AEON Biopharma stock for Q2 2024, down 92% quarter-over-quarter.
- 4 funds opened new AEON Biopharma positions in Q2 2024 and 6 closed out, a net change of -2 holders.
- The largest AEON Biopharma buyer in Q2 2024 was Davidson Kempner Capital Management, an estimated $298K added.
- The largest AEON Biopharma seller in Q2 2024 was Goldman Sachs, an estimated $522K sold.
Based on aggregated 13F filings for Q2 2024.